PŘEHLEDOVÉ ČLÁNKY / REVIEW ARTICLES Maligní hypertermie „up‑to‑date prakticky“ – nesystematický přehledový článek | 83 / Anest intenziv Med. 2025;36(2):74-83 / ANESTEZIOLOGIE A INTENZIVNÍ MEDICÍNA www.aimjournal.cz www.csarim.cz/getmedia/bf2afe85-bd5b-4050-acd6-0cd4583aff9b/doporuceny‑postup ‑zasady‑bezpecne‑anesteziologicke‑pece-2017.pdf.aspx. 42. Heiderich S, Thoben C, Dennhardt N, Koppert W, Krauß T, Sümpelmann R, et al. Low anaesthetic waste gas concentrations in postanaesthesia care unit: A prospective observational study. Eur J Anaesthesiol. 2018 Jul;35(7):534-8. 43. Maryansky A, Rose JC, Rosenblatt MA, Lai YH. Postoperative Hyperthermia and Hemodynamic Instability in a Suspected Malignant Hyperthermia–Susceptible Patient: A Case Report. AA Pract [Internet]. 2021 Jan 15(1):e01314. [cited 2024 Dec 16]. Available from: https://journals.lww.com/aacr/abstract/2021/01000/postoperative_hyperthermia_and_hemodynamic.13.aspx. 44. Heytens L, Forget P, Scholtès JL, Veyckemans F. The changing face of malignant hyperthermia: less fulminant, more insidious. Anaesth Intensive Care. 2015 Jul;43(4):506-11. 45. Visoiu M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg. 2014 Feb;118(2):388-96. 46. Snoeck MM, Gielen MJ, Tangerman A, van Egmond J, Dirksen R. Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane. Acta Anaesthesiol Scand. 2000 Mar;44(3):334-7. 47. Pollock AN, Langton EE, Couchman K, Stowell KM, Waddington M. Suspected malignant hyperthermia reactions in New Zealand. Anaesth Intensive Care. 2002 Aug;30(4):453-61. 48. Riazi S, Bersselaar LR van den, Islander G, Heytens L, Snoeck MMJ, Bjorksten A, et al. Pre‑operative exercise and pyrexia as modifying factors in malignant hyperthermia (MH). Neuromuscul Disord NMD. 2022 Aug;32(8):628-34. 49. Hardy JB, Gouin A, Damm C, Compère V, Veber B, Dureuil B. The use of a checklist improves anaesthesiologists’ technical and non‑technical performance for simulated malignant hyperthermia management. Anaesth Crit Care Pain Med. 2018 Feb;37(1):17-23. 50. Hopkins PM. Recrudescence of malignant hyperthermia. Anesthesiology. 2007 May;106(5):893-4. 51. Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology. 2007 May;106(5):901-6; quiz 1077-8. 52. Grodofsky S, Levitt C, Schlichter RA, Stanton DC, Liu R, Chen L. Upper extremity deep vein thrombosis in a patient treated for malignant hyperthermia. J Clin Anesth. 2013 Jun;25(4):350-2. 53. Brandom BW, Larach MG, Chen MSA, Young MC. Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesth Analg. 2011 May;112(5):1115-23. 54. Migita T, Mukaida K, Yasuda T, Hamada H, Kawamoto M. Calcium channel blockers are inadequate for malignant hyperthermia crisis. J Anesth. 2012 Aug;26(4):579-84. 55. Laurence AS, Vanner GK, Collins W, Hopkins PM. Serum and urinary myoglobin following an aborted malignant hyperthermia reaction. Anaesthesia. 1996 Oct;51(10):958-61. 56. Litman RS, Flood CD, Kaplan RF, Kim YL, Tobin JR. Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry. Anesthesiology. 2008 Nov;109(5):825-9. 57. Min JY, Hong SH, Kim SJ, Chung MY. Delayed‑onset malignant hyperthermia in the postanesthetic care unit: a case report. J Int Med Res. 2021 Sep;49(9):3000605211044201. 58. Papadimos TJ, Almasri M, Padgett JC, Rush JE. A suspected case of delayed onset malignant hyperthermia with desflurane anesthesia. Anesth Analg. 2004 Feb;98(2):548-9. 59. Pinyavat T, Riazi S, Deng J, Slessarev M, Cuthbertson BH, Ibarra Moreno CA, et al. Malignant Hyperthermia. Crit Care Med [Internet]. 2024 Dec 52(12):1934. [cited 2024 Dec 16]. Available from: https://journals.lww.com/ccmjournal/fulltext/2024/12000/malignant_ hyperthermia.14.aspx. 60. Klucka J, Kosinova M, Zacharowski K, De Hert S, Kratochvil M, Toukalkova M, et al. Rapid sequence induction: An international survey. Eur J Anaesthesiol. 2020 Jun;37(6):435-42. 61. Larach MG, Klumpner TT, Brandom BW, Vaughn MT, Belani KG, Herlich A, et al. Succinylcholine Use and Dantrolene Availability for Malignant Hyperthermia Treatment: Database Analyses and Systematic Review. Anesthesiology. 2019 Jan;130(1):41-54. 62. Gorsky K, Cuninghame S, Chen J, Jayaraj K, Withington D, Francoeur C, et al. Use of inhalational anaesthetic agents in paediatric and adult patients for status asthmaticus, status epilepticus and difficult sedation scenarios: a protocol for a systematic review. BMJ Open. 2021 Nov 10;11(11):e051745. 63. Pasrija D, Assioun J, Sallam M, Prout A. Inhalational Anesthesia for Near‑fatal Pediatric Asthma Complicated by Malignant Hyperthermia. Cureus. 2021 Oct;13(10):e19032. 64. Wendlandt B, Turinsky S, Schmitz M. Isoflurane‑induced malignant hyperthermia during intensive‑care treatment. Med Klin Intensivmed Notfallmedizin. 2015 Apr;110(2):155-8. 65. Rosenberg H, Gronert GA. Intractable cardiac arrest in children given succinylcholine. Anesthesiology. 1992 Nov;77(5):1054. 66. Heytens K, De Bleecker J, Verbrugghe W, Baets J, Heytens L. Exertional rhabdomyolysis and heat stroke: Beware of volatile anesthetic sedation. World J Crit Care Med. 2017 Feb 4;6(1):21-7. 67. Lavezzi WA, Capacchione JF, Muldoon SM, Sambuughin N, Bina S, Steele D, et al. Case report: Death in the emergency department: an unrecognized awake malignant hyperthermia‑like reaction in a six‑year‑old. Anesth Analg. 2013 Feb;116(2):420-3. 68. Cummings T, Der T, Karsli C. Repeated nonanesthetic malignant hyperthermia reactions in a child. Paediatr Anaesth. 2016 Dec;26(12):1202-3. 69. Zvaritch E, Gillies R, Kraeva N, Richer M, Jungbluth H, Riazi S. Fatal awake malignant hyperthermia episodes in a family with malignant hyperthermia susceptibility: a case series. Can J Anaesth J Can Anesth. 2019 May;66(5):540-5. 70. Groom L, Muldoon SM, Tang ZZ, Brandom BW, Bayarsaikhan M, Bina S, et al. Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress‑induced malignant hyperthermia in two unrelated families. Anesthesiology. 2011 Nov;115(5):938-45. 71. Wappler F, Fiege M, Steinfath M, Agarwal K, Scholz J, Singh S, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise‑induced rhabdomyolysis. Anesthesiology. 2001 Jan;94(1):95-100. 72. Kruijt N, den Bersselaar LV, Snoeck M, Kramers K, Riazi S, Bongers C, et al. RYR1-Related Rhabdomyolysis: A Spectrum of Hypermetabolic States Due to Ryanodine Receptor Dysfunction. Curr Pharm Des. 2022;28(1):2-14. 73. Timmins MA, Rosenberg H, Larach MG, Sterling C, Kraeva N, Riazi S. Malignant hyperthermia testing in probands without adverse anesthetic reaction. Anesthesiology. 2015 Sep;123(3):548-56. 74. Girard T. Malignant hyperthermia during pregnancy [Internet]. EMHG. 2019 [cited 2024 Dec 16]. Available from: https://www.emhg.org/recommendations-1/mh‑during ‑pregnancy. 75. Štourač P, Štěpánková D, Klincová M, Schröderová I, Zídková J, Gaillyová R, et al. Algoritmus diagnostiky maligní hypertermie. Operativní doporučení. [Internet]. NIKEZ. 2025 [cited 2025 March 30]. Available from: https://nikez.mzcr.cz/guideline/354-algoritmus ‑diagnostiky‑maligni‑hypertermie/.
RkJQdWJsaXNoZXIy NDA4Mjc=